Kintari Branded Skin Care Products to Entering the Asian Marketplace
LAS VEGAS, NV and SHENZHEN, CHINA / ACCESSWIRE / September 8, 2016 / Skinvisible Inc., (SKVI), through its subsidiary Kintari Int. Inc., and EDFA Morgan Capital Co. LTD. (“EMC”) (NEEQ:838957) located in Shenzhen, China, have signed an exclusive distribution agreement for Kintari® branded products for the territory of Greater China (Includes China, Hong Kong, Macau, Taiwan, Singapore, Malaysia and Thailand).
According to the agreement, EMC will sell Kintari products to Chinese consumers through a network of online shopping malls and other channels. In addition to their local market expertise, EMC has agreements with extensive sales and distribution networks in Greater China. Kintari will supply its portfolio of globally patented skincare products made with its Invisicare® delivery technology.
“We are pleased to enter into this agreement with EMC as they have excellent access to international distribution channels,” said Terry Howlett, President of Kintari Int. Inc. “This agreement marks a significant milestone in Kintari’s business strategy to develop strong relationships with established marketing and distribution channels for our products. This agreement exemplifies our shared vision for accelerated and sustainable growth in future product sales and we look forward to a long, successful partnership.”
“We are pleased to enter into this distribution agreement with Kintari for its high quality products,” said Alexander McCoy, Director of EMC. “EMC is uniquely capable of introducing Kintari’s products throughout our extensive network in Greater China. We are looking forward to this opportunity and believe this will increase revenues and bring additional business for both companies in the short and long-term.”
China, with a population of over 1.6 billion people, has a strong demand for American-made products. This is driven both by the growth of a middle class in large cities as well as the increased desire for high quality products made in America. Last year China imported $2.7 billion personal care products (skincare, sun care, etc.) (Source:Global Trade Atlas). According to HKTDC Research; 69% of females surveyed would buy skincare products and cosmetics from online stores and spend an average of US$1800 a year on them.
This distribution agreement is consistent with Skinvisible’s business model which includes driving revenue from the sale of its Kintari branded products through its subsidiaries Kintari USA and Kintari Canada and through international distribution and licensing agreements.
About Skinvisible Pharmaceuticals, Inc. / Kintari Int. Inc.
Skinvisible Pharmaceuticals is a R&D company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Kintari Int. Inc., a wholly-owned subsidiary markets its cosmeceutical and OTC products.
www.skinvisible.com, www.invisicare.com, www.kintari.com
About EDFA Morgan Capital Corporation (“EMC”)
EDFA Morgan Capital Co., LTD. (“EMC”) is located in the Futian Duty Free Zone in Shenzhen, China and is a wholly-owned subsidiary of EDFA Smart-Eco Holdings Co., LTD. (“EDFA”). EDFA, which trades on the Beijing stock exchange (NEEQ:838957), is an 11 year old company which specializes in city development including finance, strategic planning, deployment, construction, engineering and urban design. EDFA’s subsidiary EMC has the sole objective to integrate Internet technologies with manufacturing and business (referred to as “Internet Plus”) which includes developing a large cloud e-commerce platform featuring top American-made products to be supplied to the Greater China region. www.edfadesign.com
Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending June 30, 2016).
John Pentony is a consultant to Skinvisible and is currently being paid nineteen hundred dollars for a program that covers the Company through January 18, 2017. There are no shares, warrants or other equity related compensation. Mr. Pentony previously represented Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock.